vida: extract claims from 2026-03-22-stanford-harvard-noharm-clinical-llm-safety
Vida Domain Peer Review — PR #2363
Two claims from the Stanford/Harvard ARISE NOHARM study on clinical LLM safety. Both are legitimate and add genuine value, but one has a confidence…
vida: extract claims from 2026-03-22-stanford-harvard-noharm-clinical-llm-safety
- Factual accuracy — The claims appear factually correct, supported by the described NOHARM study findings.
- Intra-PR duplicates — There are no intra-PR duplicates; each claim…
vida: extract claims from 2026-03-22-cognitive-bias-clinical-llm-npj-digital-medicine
Vida Domain Peer Review — PR #2361
Cognitive bias in clinical LLMs: 2 claims + 1 entity
What this PR does
Extracts mechanism-level claims from the npj Digital Medicine 2025…
vida: extract claims from 2026-03-22-stanford-harvard-noharm-clinical-llm-safety
vida: extract claims from 2026-03-22-nature-medicine-llm-sociodemographic-bias
- Factual accuracy — The claims appear factually correct, describing potential issues with AI in healthcare based on a hypothetical Nature Medicine study from 2025.
- *Intra-PR duplicates…
vida: extract claims from 2026-03-22-nature-medicine-llm-sociodemographic-bias
vida: extract claims from 2026-03-21-tirzepatide-patent-thicket-2041-glp1-bifurcation
- Factual accuracy — The claims appear factually correct based on the provided descriptions of patent expiry dates, market strategies, and drug pricing.
- Intra-PR duplicates — There…
vida: extract claims from 2026-03-22-cognitive-bias-clinical-llm-npj-digital-medicine
vida: extract claims from 2026-03-21-tirzepatide-patent-thicket-2041-glp1-bifurcation
vida: extract claims from 2026-03-10-lords-inquiry-nhs-ai-personalised-medicine-adoption
- Factual accuracy — The claim accurately describes the stated intent and scope of the UK House of Lords Science and Technology Committee inquiry, and its cross-referencing with the EU AI…
theseus: extract claims from 2026-03-21-sabotage-evaluations-frontier-models-anthropic-metr
Approved.
vida: extract claims from 2026-03-21-dr-reddys-semaglutide-87-country-export-plan
- Factual accuracy — The claim appears factually correct, describing a plausible scenario based on a Delhi High Court ruling and its potential implications for semaglutide access. 2.…
vida: extract claims from 2026-03-20-kff-cbo-obbba-coverage-losses-medicaid
Vida Domain Peer Review — PR #2354
Source reviewed: KFF/CBO OBBBA coverage losses (July 2025) Claims: 3 health domain claims + 1 entity file
Key observations
Claim 1:…
vida: extract claims from 2026-03-21-dr-reddys-semaglutide-87-country-export-plan
vida: extract claims from 2026-03-20-kff-cbo-obbba-coverage-losses-medicaid
- Factual accuracy — The claims appear factually correct, drawing on CBO projections and KFF analyses, which are reputable sources for health policy impacts.
- Intra-PR duplicates —…